Cardiff Oncology Inc (CRDF) Stock Price, Quote & News

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 7570

Website: www.cardiffoncology.com

Address:

11055 Flintkote Avenue, San Diego, United States

BullRun4 Aug. 24 at 7:25 PM

$CRDF Q1 2026 will bring new data and great news from the FDA!! Hang in there and add if you can because this low price will be a thing of the pass coming early 2026. FDA AA and next will be BO!! 💰💰

2 · Reply

suphawk85 Aug. 24 at 7:02 AM

$CRDF I've held on for 4 years now, what's 6 more months?

1 · Reply

frogman2000 Aug. 23 at 11:59 AM

$CRDF latest AI prediction from GPT 5 with the July 29th presentation loaded for analysis Final confirmed ORR will most likely land around Control ~33%, 20mg ~45%, and 30mg ~53–55%, with the 30mg arm emerging as the registrational dose due to consistent dose-response and deeper tumor regression.

2 · Reply

ObscuraVertex Aug. 23 at 10:14 AM

$CRDF Cardiff Oncology Inc is a clinical stage biotech with targeted cancer therapy platform

1 · Reply

Cutlass Aug. 22 at 8:22 PM

$CRDF

0 · Reply

look2theblue Aug. 22 at 6:19 PM

$CRDF when the AI bubble bursts $PLTR $NVDA $OKLO curing cancer will still be fashionable $CRDF

2 · Reply

PSDL75 Aug. 22 at 5:06 PM

$CRDF freaking stop sweeping the leg

1 · Reply

BillionDollarDreams Aug. 22 at 2:42 PM

$CRDF glad I bought the dip now that we got J pow out the way let's see how the market moves.

2 · Reply

McGinvests Aug. 22 at 2:39 PM

$CRDF Do you know why the rich stay rich? Due to their entry point they were likely up 100% on their money. MILLIONS of dollars… for a company whose job it is… to make millions of dollars. The reason they stayed rich is because they took their millions instead of taking an unnecessary risk. That’s what biotech is… a large risk. I’m sure you would have taken your money if you had made millions. Instead, you chose to gamble (like many of us). This time, the shorts won, even though 7 people had 100% tumour reduction. One day though… the squeeze will be immense.

0 · Reply

Cossandon Aug. 21 at 9:16 PM

$CRDF If OS data are unclear, but other intermediate endpoints seem to show a clinical benefit, then accelerated approval might be the best regulatory path forward, the FDA wrote.

3 · Reply

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 11:32 AM EDT - 25 days ago

Cardiff Oncology: Data Update Resolves Some Signals

Jul 29, 2025, 4:07 PM EDT - 26 days ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jun 27, 2025, 8:30 AM EDT - 2 months ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 17, 2025, 4:39 PM EDT - 2 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 2, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 14, 2025, 9:05 AM EDT - 3 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 8, 2025, 4:05 PM EDT - 3 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 2, 2025, 3:35 AM EDT - 4 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Apr 23, 2025, 4:05 PM EDT - 4 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:10 PM EDT - 4 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:05 PM EDT - 4 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Feb 27, 2025, 9:10 PM EST - 6 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 6 months ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 24, 2025, 4:05 PM EST - 6 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 6 months ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 18, 2025, 9:19 AM EST - 6 months ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Dec 14, 2024, 9:00 AM EST - 9 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Dec 12, 2024, 5:38 AM EST - 9 months ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 10, 2024, 5:05 PM EST - 9 months ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 7:20 AM EST - 9 months ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 9 months ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Oct 30, 2024, 4:30 PM EDT - 10 months ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 4, 2024, 1:10 PM EDT - 11 months ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Mar 8, 2024, 7:37 PM EST - 1 year ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 6, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Feb 29, 2024, 8:06 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:07 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:06 PM EST - 1 year ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Jan 17, 2024, 10:30 AM EST - 1 year ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Nov 20, 2023, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 2, 2023, 9:11 PM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Sep 27, 2023, 5:56 AM EDT - 2 years ago

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

COST MLKN PRGS TRUE

Sep 26, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in September

BullRun4 Aug. 24 at 7:25 PM

2 · Reply

suphawk85 Aug. 24 at 7:02 AM

$CRDF I've held on for 4 years now, what's 6 more months?

1 · Reply

frogman2000 Aug. 23 at 11:59 AM

2 · Reply

ObscuraVertex Aug. 23 at 10:14 AM

$CRDF Cardiff Oncology Inc is a clinical stage biotech with targeted cancer therapy platform

1 · Reply

Cutlass Aug. 22 at 8:22 PM

$CRDF

0 · Reply

look2theblue Aug. 22 at 6:19 PM

$CRDF when the AI bubble bursts $PLTR $NVDA $OKLO curing cancer will still be fashionable $CRDF

2 · Reply

PSDL75 Aug. 22 at 5:06 PM

$CRDF freaking stop sweeping the leg

1 · Reply

BillionDollarDreams Aug. 22 at 2:42 PM

$CRDF glad I bought the dip now that we got J pow out the way let's see how the market moves.

2 · Reply

McGinvests Aug. 22 at 2:39 PM

0 · Reply

Cossandon Aug. 21 at 9:16 PM

$CRDF If OS data are unclear, but other intermediate endpoints seem to show a clinical benefit, then accelerated approval might be the best regulatory path forward, the FDA wrote.

3 · Reply

Imakebigmoney Aug. 21 at 9:01 PM

$CRDF i hope they go under 1 and go bankrupt since they screwed everyone that bought they deserve to go under 1

4 · Reply

User123321 Aug. 21 at 8:43 PM

$CRDF I looked this up not long ago and if memory serves me correctly the actual CEO, who let’s face it blows, owns in the neighborhood of 25k of shares that he bought with his money and that may be more than he actually owns. I’ll be glad to look it up again and repost his buys. I specifically named him for a reason.

3 · Reply

nowandagain Aug. 21 at 6:26 PM

$CRDF Does anyone wonder why exactly Commodore jumped ship 1 month before release?

3 · Reply

deebold Aug. 21 at 6:17 PM

$CRDF I am out of crdf since July,but I still look to the message boards posts. What still amazes me is no one even post about the 26 patients treated since the Dec 2024 data release and only 11 responses of the 26 for 42%. It is like they never existed,that is why I got out.

2 · Reply

Oknrv Aug. 21 at 5:05 PM

$CRDF

0 · Reply

PSDL75 Aug. 21 at 4:25 PM

$CRDF super thin volume so it's not very expensive to sink it here

0 · Reply

stevelue Aug. 21 at 3:48 PM

$CRDF the XBI (Biotech Index) is at High of the Day...Let's roll

0 · Reply

User123321 Aug. 21 at 3:45 PM

$CRDF If he, meaning the CEO, believes his own baloney, how about 1 share bought for each of the lives lost each year to mCRC. Yes buy 50,000 shares in the open market Mr Erlander. You’ve fed off the shareholders for years now and Many think we could have done much better with better Management.

2 · Reply

JanetBSmellin Aug. 21 at 2:34 PM

$CRDF Did $2.26 to $5.64 in 7 days last December. I believe we do it again EOY.

2 · Reply

Wes_Sawkill Aug. 21 at 2:08 PM

$CRDF stop it

0 · Reply

Hurricane76 Aug. 21 at 1:59 PM

$CRDF if we need grassroots... then anyone that is a true long, post about CRDF on Linkedin today. Then tomorrow, pick another social media platform. Ask any of your strategic connections to like and forward your posts.

0 · Reply

frogman2000 Aug. 21 at 12:34 PM

$CRDF Retail needs to start wagging the dog here. Facebook post forwarding their website, X, Instgtam, LinkedIn, any others that people frequent. Start spreading the word and doing so daily and weekly as if it is your company because after all it is. Too much posting on stock boards with an echo chamber audience. Post and tag people and news organizations etc… the wave will start small but it will build.

1 · Reply

Market Cap	154.34M
Revenue (ttm)	680,000.00
Net Income (ttm)	-45.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,680.88%
Debt to Equity Ratio	0.00

Volume	1,018,500
Avg Vol	2,084,106
Day's Range	N/A - N/A
Shares Out	66.53M
Stochastic %K	30%
Beta	1.54
Analysts	Strong Sell
Price Target	$10.50